179
9
25
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4026 |
SU5408
VEGFR2 Kinase Inhibitor I |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
SU5408 (VEGFR2 Kinase Inhibitor I) 是一种可渗透细胞的VEGFR2激酶抑制剂,其IC50=70 nM。 | |||
T9724 |
VEGFR2-IN-2
|
Others | Others |
VEGFR2-IN-2 具有抗炎和镇痛活性。 | |||
T61899 |
VEGFR2-IN-1
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
VEGFR2-IN-1 是一种具有选择性和高效性的 VEGFR2 抑制剂,具有抗肿瘤活性,可抑制细胞的增殖和迁移,可用于研究乳腺癌。 | |||
T37079 |
VEGFR2 Kinase Inhibitor II
|
||
Vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR and FLK1) is a receptor tyrosine kinase that regulates angiogenesis, vascular development, and embryonic hematopoiesis in response to VEGF isoforms A, C, and D. VEGFR2 kinase inhibitor II is a reversible, cell-permeable inhibitor of VEGFR2's kinase activity (IC50 = 70 nM). It less potently inhibits the platelet-derived growth factor receptor β (PDGFRβ; IC50 = 920 nM) and related receptor and non-receptor tyrosine kinases. V... | |||
T79009 |
VEGFR2-IN-3
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
VEGFR2-IN-3 (compound 385)为高效VEGFR2抑制剂。 | |||
T80873 |
VEGFR2/HDAC1-IN-1
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
VEGFR2/HDAC1-IN-1(compound 13)是一款有效的VEGFR-2和HDAC双重抑制剂,其IC50值分别为57.83 nM 和9.82 nM 。该化合物能够阻滞细胞周期于S期及G2期,并能诱导HeLa细胞发生凋亡,同时具有抗血管生成的特性。 | |||
T78759 |
VEGFR2-IN-4
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
VEGFR2-IN-4(化合物25)为一种针对VEGFR2激酶的有效且选择性抑制剂,其GI50为0.7 nM。该化合物表现出抗血管生成活性,可用于类风湿关节炎研究领域。 | |||
T78845 |
FGFR1/VEGFR2-IN-1
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
FGFR1/VEGFR2-IN-1 (compound 2b) 为FGFR1/VEGFR2抑制剂,适用于癌症研究。 | |||
T72713 |
PI3K/VEGFR2-IN-1
|
PI3K | PI3K/Akt/mTOR signaling |
PI3K/VEGFR2-IN-1是一种具有双重抑制效应的化合物,对PI3K和VEGFR2的IC50分别为2.21 μM和68 μM,能够诱导细胞凋亡(apoptosis),在癌症研究中应用。 | |||
T3566 |
SU5205
SU 5205 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
SU5205 是一种 VEGFR2 (FLK-1) 的抑制剂,其IC50=9.6 μM。 | |||
T21593 |
AAL-993
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
AAL-993 是口服有效的VEGFR 选择性抑制剂,抑制 VEGFR1、VEGFR2 和 VEGFR3 的IC50分别为 130 nM、23 nM 和 18 nM,对其他酪氨酸激酶的抑制作用较弱。AAL-993 具有抗血管生成和抗肿瘤的活性。 | |||
T3569 |
SU5214
SU 5214 |
VEGFR; Tyrosinase | Angiogenesis; Proteases/Proteasome; Tyrosine Kinase/Adaptors |
SU5214 (SU 5214) 是 VEGFR2 抑制剂,IC50值为 14.8 µM(FLK-1) 和 36.7 µM (EGFR)。 | |||
T9052 |
XL092
CL-092,JUN04542 |
VEGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
XL092 (JUN04542) 是一种ATP 竞争性的、口服有效的多受体酪氨酸激酶 (RTKs) 抑制剂,在细胞分析中的MET (IC50:15 nM)、VEGFR2 (IC50:1.6 nM)、AXL (IC50:3.4 nM) 和 MER (IC50:7.2 nM)。它具有抗肿瘤作用,具有用于研究激酶依赖性疾病的潜力。 | |||
T2372 |
Ponatinib
帕纳替尼,AP24534,普纳替尼 |
VEGFR; FGFR; Bcr-Abl; PDGFR; Src; c-Kit; Autophagy | Angiogenesis; Autophagy; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Ponatinib (AP24534) 是一种有口服活性的多靶点激酶抑制剂,抑制Abl、PDGFRα、VEGFR2、FGFR1和Src 的IC50分别为 0.37 nM、1.1 nM、1.5 nM、2.2 nM 和 5.4 nM。 | |||
T35570 |
Chiauranib
CS2164,西奥罗尼 |
c-Fms; VEGFR; FLT; PDGFR; c-Kit; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
Chiauranib 是一种针对肿瘤血管生成的多靶点抑制剂,具有强大的抗癌作用。 Chiauranib 有效抑制血管生成相关激酶(VEGFR1、VEGFR2、VEGFR3、PDGFRα 和 c-Kit)、有丝分裂相关激酶 Aurora B 和慢性炎症相关激酶 CSF1R,IC50 值范围为 1-9 nM。 | |||
T40581 |
TIE-2/VEGFR-2 kinase-IN-2
|
||
TIE-2/VEGFR-2 kinase-IN-2 is a powerful inhibitor of both VEGFR2 and Tie-2 kinases, displaying noteworthy pIC 50 values of 8.61 and 8.56, respectively. This compound acts as an anti-angiogenic agent, making it highly relevant for cancer research. | |||
T8817 |
TIE-2/VEGFR-2 kinase-IN-1
|
||
TIE-2/VEGFR-2 kinase-IN-1 用于合成TIE-2或者VEGFR-2抑制剂,可用于研究不适当的血管生成的相关疾病。 | |||
T6479 |
Dovitinib lactate hydrate
Dovitinib (TKI258) Lactate,多韦替尼,Dovitinib Lactate,TKI258 |
VEGFR; FGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Dovitinib lactate hydrate (TKI258) 是一种多靶点的酪氨酸激酶抑制剂,抑制 FLT3,c-Kit,FGFR1/3,VEGFR1/2/3和 PDGFRα/β的 IC50值分别为 1,2,8/9,10/13/8,27/210 nM。 | |||
T4349 |
Sitravatinib
MG516,MGCD516 |
Discoidin Domain Receptor (DDR); VEGFR; FLT; Trk receptor; TAM Receptor; c-Kit; Ephrin Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
Sitravatinib (MGCD516) 是一种有口服活性的受体酪氨酸激酶抑制剂。它单独使用即具有有效的抗肿瘤功效,且通过促进抗肿瘤免疫微环境增强了 PD-1 阻断的活性。 | |||
TQ0321 |
BIBF 1202
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
BIBF 1202是 BIBF 1120的羧酸盐代谢物。BIBF 1202抑制 VEGFR2激酶的 IC50值为62 nM。 | |||
T2421 |
SKLB1002
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
SKLB1002 是一种有效的 ATP 竞争性 VEGFR2 抑制剂,IC50 为 32 nM。 | |||
T1991 |
ZM323881 hydrochloride
ZM 323881 hydrochloride,ZM 323881 HCl |
EGFR; VEGFR; FGFR; PDGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
ZM323881 hydrochloride (ZM 323881 HCl) 是一种选择性的VEGFR2抑制剂,其IC50<2 nM。 | |||
T2446 |
KI8751
|
EGFR; VEGFR; FGFR; PDGFR; c-Kit | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Ki8751 是一种有效的 VEGFR2 抑制剂,其 IC50=0.9 nM。 | |||
T17219 |
Vatalanib free base
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Vatalanib free base 是一种 VEGFR2/KDR 的抑制剂,其IC50=37nM。 | |||
T22737 |
DMH4
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
DMH4 是一种有效的选择性 VEGFR2 抑制剂,其 IC50 为 0.16 µM。 | |||
T6036 |
Brivanib
BMS-540215,布立尼布 |
EGFR; VEGFR; FGFR; Autophagy | Angiogenesis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Brivanib (BMS-540215) 是一种针对 VEGFR2 的 ATP 竞争性抑制剂,IC50 为 25 nM。它对 VEGFR-1 和 FGFR-1 具有中等效力,对 VEGFR2 的选择性是对 PDGFR-β 的 240 倍。 | |||
T3980 |
Su1498
Tyrphostin SU 1498,AG 1498 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Su1498 (Tyrphostin SU 1498) 是一种选择性的 VEGFR2 抑制剂,能够抑制 Flk-1 (IC50:700 nM)。 | |||
T2419 |
BMS-794833
|
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
BMS794833 是一种 VEGFR2 和 Met 的抑制剂,它们的 IC50值分别为 15 和 1.7 nM。 | |||
T1836 |
AZD2932
|
VEGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
AZD2932是一种多靶点激酶抑制剂,细胞试验中能够抑制 VEGFR2 (IC50:8 nM),PDGFβ (IC50:4 nM),PDGFβ (IC50:7 nM) 和 PDGFβ (IC50:9 nM)。 | |||
T6996 |
SU 5402
SU5402 |
VEGFR; FGFR; PDGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
SU 5402 是多靶点受体酪氨酸激酶抑制剂,能够抑制VEGFR2 (IC50:20 nM),FGFR1 (IC50:30 nM),PDGFRβ (IC50:510 nM)。 | |||
T2642 |
PD173074
|
Apoptosis; EGFR; VEGFR; FGFR; IGF-1R; Src | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
PD173074 是一种 FGFR1抑制剂,IC50为 25 nM。它也可抑制 VEGFR2活性,IC50值为 100-200 nM。 | |||
T12598 |
Pz-1
|
VEGFR; c-RET | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Pz-1 是 VEGFR2 和 RET 酪氨酸激酶的抑制剂,可阻断 RET 刺激生长所需的血液供应。 | |||
T2576 |
Brivanib (alaninate)
丙氨酸布立尼布,BMS-582664,Brivanib Alaninate |
VEGFR; FGFR; Autophagy | Angiogenesis; Autophagy; Tyrosine Kinase/Adaptors |
Brivanib Alaninate (BMS-582664) 是一种血管内皮生长因子受体 2 (VEGFR2) 抑制剂的丙氨酸盐,IC50值为 25 nM,具有潜在的抗肿瘤活性。它对 VEGFR1 和 FGFR1 适度抑制,对 VEGFR2 的选择性是对 PDGFRβ 的 240 倍。 | |||
T2064 |
Semaxinib
司马沙尼,SU5416 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Semaxinib (SU5416) 是一种选择性的 VEGFR(Flk-1/KDR) 抑制剂,其 IC50=1.23 μM。 | |||
T13157 |
TG 100801
TG100801,TG 100572 |
VEGFR; Src | Angiogenesis; Tyrosine Kinase/Adaptors |
TG 100801 是 VEGFr2 和 Src 家族(Src 和 YES)激酶的双重抑制剂,是治疗年龄相关性黄斑变性(AMD)的候选化合物。 | |||
T22436 |
Takeda-6d
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Takeda-6d 是一种新型、有效的 DFG-out RAF/血管内皮生长因子受体 2 (VEGFR2) 抑制剂,IC50 分别为 7.0 nM 和 2.2 nM。 | |||
T6720 |
Vatalanib dihydrochloride
CGP-797870 dihydrochloride,ZK-222584 dihydrochloride,Vatalanib 2HCl,PTK787 dihydrochloride,Vatalanib (PTK787) 2HCl,CGP-79787 dihydrochloride,瓦他拉尼 |
Apoptosis; VEGFR; PDGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Vatalanib dihydrochloride (PTK787 dihydrochloride) 是一种VEGFR2/KDR 的抑制剂,其IC50值为37nM。 | |||
T6137 |
KRN-633
KRN633,N-[2-氯-4-[(6,7-二甲氧基-4-喹唑啉基)氧基]苯基]-N'-丙基脲 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
KRN-633 是一种 VEGFR 抑制剂,能够一种 VEGFR1 (IC50:170 nM)、VEGFR2 (IC50:160 nM)、VEGFR3 (IC50:125 nM)。 | |||
T2056L |
UNC0064-12 hydrochloride (1430089-64-7(free base))
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
UNC0064-12 hydrochloride (1430089-64-7(free base)) 是一种VEGFR2 抑制剂。 | |||
T4318 |
EOC317
ACTB-1003,ACTB1003,ACTB 1003 |
VEGFR; FGFR; Tie-2 | Angiogenesis; Tyrosine Kinase/Adaptors |
EOC317 (ACTB-1003) 是一种口服可用的激酶抑制剂,能够抑制 FGFR1 (IC50:6 nM),VEGFR2 (IC50:2 nM) 和 Tie-2 (IC50:4 nM)。 | |||
T8326 |
BMS-2
1-(4-氟苯基)-N-[3-氟-4-(1H-吡咯并[2,3-B]吡啶-4-基氧基)苯基]-1,2-二氢-2-氧代-3-吡啶甲酰胺 |
VEGFR; FLT; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
BMS-2 是 Met/Flt-3/VEGFR2 酪氨酸激酶抑制剂。 | |||
T28077 |
MMPP
|
VEGFR; STAT | Angiogenesis; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
MMPP 是一种新型 VEGFR2 抑制剂,具有抗炎活性和潜在的抗癌活性,抑制STAT3 ,可通过 VEGFR2/AKT/ERK/NF-kappaB 通路抑制血管生成,可用于缓解心肌损伤。 | |||
T16975 |
TAK-593
|
VEGFR; PDGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
TAK-593 是一种 VEGFR2 和 PDGFR 抑制剂,能够作用于VEGFR1 (IC50:3.2 nM)、VEGFR2 (IC50:0.95 nM)、VEGFR3 (IC50:1.1 nM)、PDFGRα (IC50:4.3 nM)、PDFGRβ (IC50:13 nM)。 | |||
TQ0021 |
Ningetinib
CT-053,CT053PTSA,宁格替尼 |
VEGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
Ningetinib (CT-053) 是口服具有活力的、小分子酪氨酸激酶抑制剂,能够抑制 c-Met (IC50:6.7 nM),VEGFR2 (IC50:1.9 nM) 和 Axl (IC50<1.0 nM)。 | |||
T3599 |
BFH772
BFH-722 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
BFH772 是 VEGFR2抑制剂(IC50:3 nM),具有口服活性。 | |||
T6166 |
Telatinib
Bay 57-9352,替拉替尼 |
VEGFR; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Telatinib (Bay 57-9352) 是一种口服具有活力的,小分子的 VEGFR2,VEGFR3,PDGFα 和 c-Kit 抑制剂,它们的 IC50 值分别为6,4,15,1 nM。 | |||
T1656 |
Vandetanib
ZD6474,凡德他尼 |
Apoptosis; EGFR; VEGFR; Autophagy | Angiogenesis; Apoptosis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Vandetanib (ZD6474) 是一种具有口服活性的VEGFR2/KDR 酪氨酸激酶抑制剂,IC50值为40 nM。它也抑制VEGFR3/FLT4和EGFR/HER1,IC50值分别为110和500 nM。 | |||
T7945 |
SU14813
|
VEGFR; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
SU14813 是一种多靶点受体酪氨酸激酶抑制剂,能够抑制 VEGFR2 (IC50:50 nM),VEGFR1 (IC50:2 nM),PDGFRβ (IC50:4 nM),KIT (IC50:15 nM)。 | |||
T6351 |
MGCD-265 analog
MGCD-265,Glesatinib |
Apoptosis; VEGFR; c-Met/HGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
MGCD-265 analog (Glesatinib) 是一种口服生物可利用的多靶点酪氨酸激酶抑制剂,具有抗肿瘤活性,对 c-Met 和 VEGFR2 的 IC50 分别为 29 nM 和 10 nM。 | |||
T6296 |
RAF265
CHIR-265 |
Apoptosis; Raf; VEGFR; Autophagy | Angiogenesis; Apoptosis; Autophagy; MAPK; Tyrosine Kinase/Adaptors |
RAF265 (CHIR-265) 是一种 RAF/VEGFR2抑制剂。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TJS0339 |
Coumarin-3-carboxylic acid
香豆素-3-羧酸,3-Carboxycoumarin |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Coumarin-3-carboxylic acid (3-Carboxycoumarin) 是一种合成香豆素的重要起始化合物。其中香豆素是具有多种生物活性的天然产物。它的镧系复合物对 K-562 细胞具有抗增殖活性。 | |||
T2906 |
Tanshinone IIA
丹参酮IIA,Tanshinone B,Dan Shen ketone |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Tanshinone IIA (Tanshinone B) 是红根丹参根系中的一种主要组合物。它能够利用靶向 VEGF/VEGFR2的蛋白激酶结构域,抑制血管生成。 | |||
T1644 |
Dopamine hydrochloride
盐酸多巴胺,Dopamine HCl,ASL279 |
Ferroptosis; Dopamine Receptor; 5-HT Receptor; Endogenous Metabolite | Apoptosis; GPCR/G Protein; Metabolism; Neuroscience |
Dopamine hydrochloride (ASL279) 是在脑黑质、脑腹侧被盖区和下丘脑中产生的一种天然儿茶酚胺,由二羟基苯丙氨酸脱羧形成,是去甲肾上腺素和肾上腺素的前体。它通过 D2 多巴胺受体来诱导 VEGFR2 的内吞作用,有促进血管生成活性。 | |||
T13108 |
Pamufetinib
H2OL3Q4XRD,4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide,TAS-115 |
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Pamufetinib (TAS-115) 是VEGFR 和c-Met/HGFR 抑制剂,能够抑制 rVEGFR2 (IC50:30 nM)和 rMET (IC50:32 nM)的活性。 | |||
T15542 |
Hypothemycin
|
Others | Others |
Hypothemycin is a fungal polyketide and is a multikinase inhibitor (Kis: 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2, respectively). | |||
TN6682 | Cyclo(Phe-Gly) | ||
Cyclo(Phe-Gly) shows weak antagonistic activity against VEGFR2 -CD, it also shows strong inhibitory activity against human cancer cells(KB,KBv200) with LD50 at 6.5 and 11.2 umol/L,respectively. | |||
T3S0153 |
Xanthatin
苍耳亭,叶黄制菌素 |
Apoptosis; VEGFR; Lipoxygenase; Wnt/beta-catenin; Antibacterial | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Metabolism; Microbiology/Virology; Stem Cells; Tyrosine Kinase/Adaptors |
Xanthatin 是一种从Xanthium strumarium 叶子中提取的天然产物,可诱导细胞凋亡。它抑制布鲁氏菌的IC50值为 2.63 μg/ mL,对寄生虫特异性锥虫硫磷还原酶具有不可逆的弱抑制作用。它通过抑制PGE2的合成和 5-脂氧合酶的活性而显示出抗炎活性。 | |||
TN6678 |
Cyclo(Tyr-Pro)
|
||
Cyclo(Tyr-Pro) shows antibacterial activity towards several marine bacterial species, it also shows weak antagonistic activity against VEGFR2 -CD. Cyclo(Tyr-Pro) and cyclo(Pro-Val) are toxic to both suspension cells and seedlings of Pinus thunbergii, whic | |||
T14055 |
5Z-7-Oxozeaenol
FR148083,L783279,LL-Z 1640-2 |
VEGFR; FLT; MEK; MAPK; PDGFR; Antibiotic; Src | Angiogenesis; MAPK; Microbiology/Virology; Tyrosine Kinase/Adaptors |
5Z-7-Oxozeaenol (FR148083) 是一种天然抗原生动物抑制剂,不可逆的选择性抑制 TAK1和 VEGF-R2,IC50值分别为 8 nM 和 52 nM。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-02361 |
VEGFR2/KDR Protein, Human, Recombinant (His)
VEGFR2,kinase insert domain receptor,V... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 84.6 kDa and the accession number is P35968-1. | |||
TMPY-01044 |
VEGFR2/KDR Protein, Human, Recombinant (hFc)
Flk-1,CD309,FLK1,VEGFR2,VEGFR,kin... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 109 kDa and the accession number is P35968-1. | |||
TMPY-05657 |
VEGFR2/KDR Protein, Human, Recombinant (hFc), Biotinylated
VEGFR2,Flk-1,kinase insert domain receptor... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (hFc), Biotinylated is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 61.5 kDa and the accession number is P35968-1. | |||
TMPY-04530 |
VEGFR2/KDR Protein, Human, Recombinant (His & GST)
Flk-1,VEGFR2,kinase insert domain receptor... |
Human | Baculovirus Insect Cells |
VEGFR2/KDR Protein, Human, Recombinant (His & GST) is expressed in Baculovirus insect cells with His and GST tag. The predicted molecular weight is 89.3 kDa and the accession number is P35968-1. | |||
TMPK-00645 |
VEGFR2/KDR Protein, Rhesus macaque, Recombinant (His)
KRD1,VEGFR2,FLK1,CD309,Ly73,VEGFR... |
Rhesus | HEK293 Cells |
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. The tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of angiogenesis. VEGFR2/KDR Protein, Rhesus macaque, Recombinant (His) is expressed in HEK293 mammalian cells with ... | |||
TMPY-04940 |
VEGFR2/KDR Protein, Human, Recombinant (His), Biotinylated
Flk-1,kinase insert domain receptor,VEGFR,CD309, |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 84.6 kDa and the accession number is P35968-1. | |||
TMPK-00454 |
VEGFR2/KDR Protein, Human, Recombinant (His & Avi)
VEGFR-21,Ly73,KRD1,VEGFR2 |
Human | HEK293 Cells |
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. The tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of angiogenesis. VEGFR2/KDR Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-H... | |||
TMPY-05610 |
VEGFR2/KDR Protein, Human, Recombinant (His & Avi), Biotinylated
Flk-1,VEGFR,kinase insert domain receptor,VEGFR... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag. The predicted molecular weight is 86.5 kDa and the accession number is P35968-1. | |||
TMPY-02736 |
VEGFR2/KDR Protein, Mouse, Recombinant (His)
sVEGFR-2,6130401C07,kinase insert domain r... |
Mouse | HEK293 Cells |
VEGFR2/KDR Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 84.5 kDa and the accession number is P35918-1. | |||
TMPY-04802 |
VEGFR2/KDR Protein, Human, Recombinant (Domain 2&3, hFc)
kinase insert domain receptor,CD309,VEGFR2... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (Domain 2&3, hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 50.4 kDa and the accession number is P35968-1. | |||
TMPY-04796 |
VEGFR2/KDR Protein, Human, Recombinant (Domain 2&3, His)
FLK1,kinase insert domain receptor,CD309,VEGFR2... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (Domain 2&3, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 24.8 kDa and the accession number is P35968-1. | |||
TMPY-04794 |
VEGFR2/KDR Protein, Human, Recombinant (Domain 1&2&3, hFc)
VEGFR,kinase insert domain receptor,Flk-1,VEGFR... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (Domain 1&2&3, hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 61.5 kDa and the accession number is P35968-1. | |||
TMPY-04795 |
VEGFR2/KDR Protein, Human, Recombinant (Domain 1&2&3, His)
kinase insert domain receptor,VEGFR2,FLK1,... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (Domain 1&2&3, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 35.9 kDa and the accession number is P35968-1. | |||
TMPY-04924 |
VEGFR2/KDR Protein, Mouse, Recombinant (His), Biotinylated
VEGFR-2,6130401C07,Ly73,Krd-1,kinase inser... |
Mouse | HEK293 Cells |
VEGFR2/KDR Protein, Mouse, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 84.5 kDa and the accession number is P35918-1. | |||
TMPY-02858 |
VEGFR2/KDR Protein, Mouse, Recombinant (hFc)
VEGFR2,6130401C07,Krd-1,kinase insert doma... |
Mouse | HEK293 Cells |
VEGFR2/KDR Protein, Mouse, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 110 kDa and the accession number is P35918. | |||
TMPJ-00593 |
VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His)
KDR,Fetal liver kinase 1,VEGFR-2,Kinase in... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His) is expressed in HEK293 mammalian cells with C-6xHis tag. The predicted molecular weight is 110-140 KDa and the accession number is AAI31823.1. | |||
TMPY-03202 |
VEGFR2/KDR Protein, Rat, Recombinant (hFc)
kinase insert domain receptor |
Rat | HEK293 Cells |
VEGFR2/KDR Protein, Rat, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 110 kDa and the accession number is Q5PQU0. | |||
TMPY-02678 |
VEGFR2/KDR Protein, Rat, Recombinant (His)
kinase insert domain receptor |
Rat | HEK293 Cells |
VEGFR2/KDR Protein, Rat, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 84.3 kDa and the accession number is A6HDB7. | |||
TMPY-05382 |
VEGFR2/KDR Protein, Cynomolgus, Recombinant (His)
kinase insert domain receptor |
Cynomolgus | HEK293 Cells |
VEGFR2/KDR Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 84.7 kDa and the accession number is G7P5T2. | |||
TMPJ-00414 |
VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His & Avi), Biotinylated
Protein-tyrosine kinase receptor flk-1,KDR,Kinase insert dom... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-6xHis-Avi tag. The predicted molecular weight is 120-150 KDa and the accession number is P35968. | |||
TMPJ-00864 |
VEGF165 Protein, Human, Recombinant
Vascular Endothelial Growth Factor Isoform 165,血管内皮生长因子,VEGF... |
Human | HEK293 Cells |
Human Vascular endothelial growth factor (VEGF), also known as VEGF-A and vascular permeability factor (VPF), belongs to the platelet-derived growth factor family of cysteine-knot growth factors. It is a potent activator in vasculogenesis and angiogenesis both physiologically and pathologically. VEGF-A has 8 differently spliced isoforms, of which VEGF165 is the most abundant one. VEGF165 is a disulfide-linked homodimer consisting of two glycosylated 165 amino acid polypeptide chains. VEGF stimul... | |||
TMPJ-00865 |
VEGF121 Protein, Human, Recombinant (His)
VEGFA,VEGF-A,Vascular permeability factor,VPF,血管内皮生长因子,Vascu... |
Human | HEK293 Cells |
Human VEGF121, also known as Vascular endothelial growth factor A, VEGFA, Vascular permeability factor, VPF and VEGF, is a homodimeric, heparin-binding glycoprotein which belongs to the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis, permeabilization of blood vessel... | |||
TMPH-01201 |
DRD2 Protein, Human, Recombinant (His & Myc)
Dopamine D2 receptor,D(2) dopamine recepto... |
Human | E. coli |
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5. | |||
TMPK-00489 |
TL1A/TNFSF15 Protein, Cynomolgus/Rhesus macaque, Recombinant (His)
TNFSF15,TNF superfamily member 15,TL1,VEGI192A,TL1A... |
Cynomolgus,Rhesus | HEK293 Cells |
TNF superfamily member 15 (TNFSF15), a cytokine largely produced by vascular endothelial cells and a specific inhibitor of the proliferation of these same cells, can inhibit VEGF-induced vascular permeability in vitro and in vivo, and that death receptor 3 (DR3), a cell surface receptor of TNFSF15, mediates TNFSF15-induced dephosphorylation of VEGFR2. TNFSF15 Protein, Cynomolgus/Rhesus macaque, Recombinant (His) is expressed in HEK293 mammalian cells with N-His tag. The predicted molecular weigh... | |||
TMPK-00143 |
TL1A/TNFSF15 Trimer Protein, Human, Recombinant (His & Flag)
TL1A,TL1,TNFSF15,VEGI,VEGI192A,VEGI-251 |
Human | HEK293 Cells |
TNF superfamily member 15 (TNFSF15), a cytokine largely produced by vascular endothelial cells and a specific inhibitor of the proliferation of these same cells, can inhibit VEGF-induced vascular permeability in vitro and in vivo, and that death receptor 3 (DR3), a cell surface receptor of TNFSF15, mediates TNFSF15-induced dephosphorylation of VEGFR2. TNFSF15 Trimer Protein, Human, Recombinant (His & Flag) is expressed in HEK293 mammalian cells with N-His-Flag tag. The predicted molecular weight... |